Federated Hermes Inc. Raises Stock Position in Elanco Animal Health Incorporated $ELAN

Federated Hermes Inc. lifted its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 9.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,379,391 shares of the company’s stock after buying an additional 197,811 shares during the period. Federated Hermes Inc.’s holdings in Elanco Animal Health were worth $47,921,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Elanco Animal Health in the first quarter valued at $2,065,000. Goldman Sachs Group Inc. increased its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after purchasing an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after purchasing an additional 76,408 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Elanco Animal Health by 8.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock valued at $169,000 after purchasing an additional 944 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Trading Up 0.4%

NYSE:ELAN opened at $24.22 on Friday. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $25.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The stock has a fifty day moving average price of $22.99 and a two-hundred day moving average price of $20.24. The stock has a market capitalization of $12.03 billion, a price-to-earnings ratio of 403.65, a PEG ratio of 3.35 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In related news, insider Rajeev A. Modi acquired 4,500 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The shares were acquired at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the transaction, the insider directly owned 123,082 shares of the company’s stock, valued at $2,625,339.06. The trade was a 3.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction on Friday, December 12th. The stock was purchased at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the acquisition, the director owned 131,773 shares in the company, valued at $2,806,764.90. This represents a 8.21% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 43,450 shares of company stock worth $937,883. 0.89% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Morgan Stanley increased their price target on shares of Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 18th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Wednesday, November 19th. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, December 10th. Finally, Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.11.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.